Rifaximin for preventing episodes of overt hepatic encephalopathy

1 Guidance

1.1 Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.